The Problem: The funded project sought to test the hypothesis that a gross feature of DNA sequence – namely base composition – can be interpreted as a signal by proteins that recognise a simple sequence motif. A screen revealed numerous candidate proteins, several of which are implicated in pluripotency, development and cancer. We chose to follow up one of these proteins, SALL4, which is expressed in stem cells. Initially, postdoctoral researcher Dr Timo Quante, in collaboration with the group of Michiel Vermeulen (Nijmegen), carried out the screen using mouse stem cells. Our team subsequently generated mutant cell lines in which SALL4 was unable to bind AT-rich DNA and found dramatic effects on the expression of AT-rich genes. We showed that SALL4 preferentially regulates expression of genes within AT-rich domains of the genome, as predicted by our hypothesis.
Relevance: SALL4 is of broad biomedical interest for several reasons:
• It is mutated in the human skeletal disorder Okihiro syndrome.
• It is a primary target for the drug thalidomide which leads to its unscheduled degradation.
• It is an essential inhibitor of differentiation that safe-guards pluripotency of stem cells
• It is over-expressed in many cancers and is a potential target for anti-cancer therapeutics
High level outcome: The existence of long domains in the mammalian genome with distinct, evolutionarily-conserved base compositions correlated with gene expression levels has been known for decades, but our SALL4 study is to our knowledge the first to provide evidence for a specific biological function. This research programme helped us to build a comprehensive mechanistic picture of the ways in which DNA sequence-mediated transcriptional modulation establishes, defines, and stabilises cell states, and how defects in this system lead to disease.